Puma Biotechnology Revenue
| PBYI Stock | USD 7.10 0.28 4.11% |
As of the 5th of February, Puma Biotechnology holds the Semi Deviation of 4.26, risk adjusted performance of 0.0881, and Coefficient Of Variation of 923.02. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Puma Biotechnology, as well as the relationship between them.
Puma Biotechnology Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3695 | Revenue |
| Last Reported | Projected for Next Year | ||
| Total Revenue | 265 M | 135.4 M |
Puma | Revenue | Build AI portfolio with Puma Stock |
The Revenue trend for Puma Biotechnology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Puma Biotechnology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Puma Biotechnology's Revenue Growth Pattern
Below is the plot of the Total Revenue of Puma Biotechnology over the last few years. Total revenue comprises all receipts Puma Biotechnology generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Puma Biotechnology's Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 230.47 M | 10 Years Trend |
|
Total Revenue |
| Timeline |
Puma Revenue Regression Statistics
| Arithmetic Mean | 124,895,403 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 97.38 | |
| Mean Deviation | 114,355,932 | |
| Median | 135,384,850 | |
| Standard Deviation | 121,626,479 | |
| Sample Variance | 14793T | |
| Range | 272.5M | |
| R-Value | 0.80 | |
| Mean Square Error | 5659T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | 19,289,031 | |
| Total Sum of Squares | 236688T |
Puma Revenue History
Other Fundumenentals of Puma Biotechnology
| Current Deferred Revenue | ||
| Cost Of Revenue | ||
| Stock Based Compensation To Revenue | ||
| Sales General And Administrative To Revenue |
Puma Biotechnology Revenue component correlations
| -0.49 | -0.76 | 0.16 | -0.34 | 0.02 | ||
| -0.49 | 0.86 | -0.25 | 0.97 | -0.05 | ||
| -0.76 | 0.86 | -0.24 | 0.79 | -0.05 | ||
| 0.16 | -0.25 | -0.24 | -0.17 | -0.95 | ||
| -0.34 | 0.97 | 0.79 | -0.17 | -0.13 | ||
| 0.02 | -0.05 | -0.05 | -0.95 | -0.13 |
Click cells to compare fundamentals
Historical and Projected quarterly revenue of Puma
Projected quarterly revenue analysis of Puma Biotechnology provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Puma Biotechnology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Puma Biotechnology's stock price.
Puma Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Puma Biotechnology is extremely important. It helps to project a fair market value of Puma Stock properly, considering its historical fundamentals such as Revenue. Since Puma Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Puma Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Puma Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Puma Biotechnology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Puma Biotechnology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Puma Biotechnology.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Puma Biotechnology on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Puma Biotechnology or generate 0.0% return on investment in Puma Biotechnology over 90 days. Puma Biotechnology is related to or competes with Eledon Pharmaceuticals, Abeona Therapeutics, Voyager Therapeutics, Atea Pharmaceuticals, Arcturus Therapeutics, Allogene Therapeutics, and Humacyte. Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to e... More
Puma Biotechnology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Puma Biotechnology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Puma Biotechnology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.77 | |||
| Information Ratio | 0.0946 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 5.25 |
Puma Biotechnology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Puma Biotechnology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Puma Biotechnology's standard deviation. In reality, there are many statistical measures that can use Puma Biotechnology historical prices to predict the future Puma Biotechnology's volatility.| Risk Adjusted Performance | 0.0881 | |||
| Jensen Alpha | 0.4764 | |||
| Total Risk Alpha | 0.1504 | |||
| Sortino Ratio | 0.0928 | |||
| Treynor Ratio | 1.27 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Puma Biotechnology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Puma Biotechnology February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0881 | |||
| Market Risk Adjusted Performance | 1.28 | |||
| Mean Deviation | 2.73 | |||
| Semi Deviation | 4.26 | |||
| Downside Deviation | 4.77 | |||
| Coefficient Of Variation | 923.02 | |||
| Standard Deviation | 4.69 | |||
| Variance | 21.96 | |||
| Information Ratio | 0.0946 | |||
| Jensen Alpha | 0.4764 | |||
| Total Risk Alpha | 0.1504 | |||
| Sortino Ratio | 0.0928 | |||
| Treynor Ratio | 1.27 | |||
| Maximum Drawdown | 43.28 | |||
| Value At Risk | (3.85) | |||
| Potential Upside | 5.25 | |||
| Downside Variance | 22.8 | |||
| Semi Variance | 18.13 | |||
| Expected Short fall | (3.05) | |||
| Skewness | 0.0906 | |||
| Kurtosis | 12.77 |
Puma Biotechnology Backtested Returns
Puma Biotechnology appears to be relatively risky, given 3 months investment horizon. Puma Biotechnology maintains Sharpe Ratio (i.e., Efficiency) of 0.0937, which implies the firm had a 0.0937 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Puma Biotechnology, which you can use to evaluate the volatility of the company. Please evaluate Puma Biotechnology's Semi Deviation of 4.26, risk adjusted performance of 0.0881, and Coefficient Of Variation of 923.02 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Puma Biotechnology holds a performance score of 7. The company holds a Beta of 0.39, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Puma Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Puma Biotechnology is expected to be smaller as well. Please check Puma Biotechnology's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Puma Biotechnology's historical price patterns will revert.
Auto-correlation | 0.51 |
Modest predictability
Puma Biotechnology has modest predictability. Overlapping area represents the amount of predictability between Puma Biotechnology time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Puma Biotechnology price movement. The serial correlation of 0.51 indicates that about 51.0% of current Puma Biotechnology price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Puma Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Puma Biotechnology reported 230.47 M of revenue. This is 96.98% lower than that of the Biotechnology sector and 68.98% lower than that of the Health Care industry. The revenue for all United States stocks is 97.56% higher than that of the company.
Puma Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Puma Biotechnology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics of similar companies.Puma Biotechnology is currently under evaluation in revenue category among its peers.
Puma Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Puma Biotechnology from analyzing Puma Biotechnology's financial statements. These drivers represent accounts that assess Puma Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Puma Biotechnology's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 123.5M | 189.0M | 204.1M | 148.4M | 170.6M | 162.1M | |
| Enterprise Value | 177.1M | 227.1M | 231.0M | 153.2M | 176.2M | 167.4M |
Puma Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Puma Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Puma Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Puma Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Puma Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Puma Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Puma Biotechnology's value.| Shares | Lsv Asset Management | 2025-06-30 | 535.7 K | Citadel Advisors Llc | 2025-06-30 | 507.8 K | Globeflex Capital, L.p. | 2025-06-30 | 452.6 K | Arrowstreet Capital Limited Partnership | 2025-06-30 | 451.6 K | Los Angeles Capital Management Llc | 2025-06-30 | 445.5 K | O'shaughnessy Asset Management Llc | 2025-06-30 | 437.7 K | Sei Investments Co | 2025-06-30 | 347.2 K | Bank Of New York Mellon Corp | 2025-06-30 | 344.1 K | Millennium Management Llc | 2025-06-30 | 334.6 K | Blackrock Inc | 2025-06-30 | 3.8 M | Vanguard Group Inc | 2025-06-30 | 3.7 M |
Puma Fundamentals
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.099 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 290.33 M | ||||
| Shares Outstanding | 50.39 M | ||||
| Shares Owned By Insiders | 15.38 % | ||||
| Shares Owned By Institutions | 71.43 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 2.98 X | ||||
| Price To Sales | 1.69 X | ||||
| Revenue | 230.47 M | ||||
| Gross Profit | 163.04 M | ||||
| EBITDA | 48.08 M | ||||
| Net Income | 30.28 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 74.08 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 2.29 X | ||||
| Cash Flow From Operations | 38.92 M | ||||
| Short Ratio | 9.67 X | ||||
| Earnings Per Share | 0.74 X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 172 | ||||
| Beta | 1.23 | ||||
| Market Capitalization | 357.78 M | ||||
| Total Asset | 213.33 M | ||||
| Retained Earnings | (1.31 B) | ||||
| Working Capital | 51.55 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
| Net Asset | 213.33 M |
About Puma Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.58) | Earnings Share 0.74 | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.